Indian high court makes landmark verdict on drug patents

In a setback for the makers of branded drugs, the Indian Supreme Court dismissed Novartis' petition for patent protection for its cancer treatment Glivec. The landmark ruling reshapes the landscape for intellectual property disputes in the country and is likely to affect many other drugmakers. The decision will be an obstacle to bringing new treatments to patients, an executive with Novartis India said.

View Full Article in:

Bloomberg · LiveMint.com/The Wall Street Journal (India) · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ